Adams D, Tournev IL, Taylor MS, Coelho T, Plante-Bordeneuve V, Berk JL, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023;30(1):1–9.

Article  PubMed  Google Scholar 

Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21.

Article  CAS  PubMed  Google Scholar 

Balwani M, Sardh E, Ventura P, Peiro PA, Rees DC, Stolzel U, et al. Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria. N Engl J Med. 2020;382(24):2289–301.

Article  CAS  PubMed  Google Scholar 

Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O’Riordan WD, Cochat P, et al. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med. 2021;384(13):1216–26.

Article  CAS  PubMed  Google Scholar 

Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507–19.

Article  CAS  PubMed  Google Scholar 

Setten RL, Rossi JJ, Han S-p. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discovery. 2019;18(6):421–46.

Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, Liang XJ. Therapeutic siRNA: state of the art. Signal Transduct Target Ther. 2020;5(1):101.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19(10):673–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Springer AD, Dowdy SF. GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid Ther. 2018;28(3):109–18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang Y. Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics. Mol Ther Nucleic Acids. 2017;6:116–32.

Article  CAS  PubMed  Google Scholar 

Bishani A, Chernolovskaya EL. Activation of innate immunity by therapeutic nucleic acids. Int J Mol Sci. 2021;22(24).

Bano N, Ehlinger C, Yang TY, Swanson M, Allen S. Considerations in the immunogenicity assessment strategy for oligonucleotide therapeutics (ONTs). AAPS J. 2022;24(5):93.

Article  CAS  PubMed  Google Scholar 

Henry SP, Arfvidsson C, Arrington J, Canadi J, Crowe D, Gupta S, et al. Assessment of the immunogenicity potential for oligonucleotide-based drugs. Nucleic Acid Ther. 2022;32:369–77.

Article  CAS  PubMed  Google Scholar 

Landmesser U, Haghikia A, Leiter LA, Wright RS, Kallend D, Wijngaard P, et al. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1. Cardiovasc Res. 2021;117(1):284–91.

Article  CAS  PubMed  Google Scholar 

Agarwal S, Simon AR, Goel V, Habtemariam BA, Clausen VA, Kim JB, Robbie GJ. Pharmacokinetics and pharmacodynamics of the small interfering ribonucleic acid, givosiran, in patients with acute hepatic porphyria. Clin Pharmacol Ther. 2020;108(1):63–72.

Article  CAS  PubMed  Google Scholar 

FDA. Draft guidance for industry: clinical pharmacology considerations for the development of oligonucleotide therapeutics. 2022. Available at https://www.fda.gov/media/159414/download. Accessed on 22 Sept 2023.

Peek VL, Lemen DM, Konrad RJ, Wen Y. A competitive ligand binding assay for detection of neutralizing antibodies against an insulin analog. J Immunol Methods. 2023;523: 113575.

Article  CAS  PubMed  Google Scholar 

Simmons E, Wen Y, Li J, Qian YW, Wong LC, Konrad RJ, Bivi N. A sensitive and drug tolerant assay for detecting anti-AAV9 antibodies using affinity capture elution. J Immunol Methods. 2023;512: 113397.

Article  CAS  PubMed  Google Scholar 

Bivi N, Swearingen CA, Shockley TE, Sloan JH, Pottanat TG, Carter QL, et al. Development and validation of a novel immunogenicity assay to detect anti-drug and anti-PEG antibodies simultaneously with high sensitivity. J Immunol Methods. 2020;486: 112856.

Article  CAS  PubMed  Google Scholar 

Bourdage JS, Cook CA, Farrington DL, Chain JS, Konrad RJ. An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. J Immunol Methods. 2007;327(1):10–7.

Article  CAS  PubMed  Google Scholar 

McGowan MP, Tardif JC, Ceska R, Burgess LJ, Soran H, Gouni-Berthold I, et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS ONE. 2012;7(11): e49006.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu RZ, Wang Y, Norris DA, Kim TW, Narayanan P, Geary RS, et al. Immunogenicity assessment of inotersen, a 2′-O-(2-methoxyethyl) antisense oligonucleotide in animals and humans: effect on pharmacokinetics, pharmacodynamics, and safety. Nucleic Acid Ther. 2020;30(5):265–75.

Article  CAS  PubMed  Google Scholar 

Lofgren JA, Dhandapani S, Pennucci JJ, Abbott CM, Mytych DT, Kaliyaperumal A, et al. Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. J Immunol. 2007;178(11):7467–72.

Article  CAS  PubMed  Google Scholar 

Li J, Schantz A, Schwegler M, Shankar G. Detection of low-affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet((R)) biolayer interferometry. J Pharm Biomed Anal. 2011;54(2):286–94.

Article  CAS  PubMed  Google Scholar 

Wadhwa M, Knezevic I, Kang HN, Thorpe R. Immunogenicity assessment of biotherapeutic products: an overview of assays and their utility. Biologicals. 2015;43(5):298–306.

Article  CAS  PubMed  Google Scholar 

Myler H, Pedras-Vasconcelos J, Phillips K, Hottenstein CS, Chamberlain P, Devanaryan V, et al. Anti-drug antibody validation testing and reporting harmonization. AAPS J. 2021;24(1):4.

Article  PubMed  Google Scholar 

Brown BD. Progress on nedosiran (DCR-PHXC) development to treat primary hyperoxaluria. AsiaTIDES: Kyoto, Japan; 2020.

Google Scholar 

Dean L. ABO Blood Group. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries. Bethesda (MD): National Center for Biotechnology Information (US); 2012.